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Abstract
Background: Argininosuccinic aciduria (ASAuria; OMIM 207900) is a rare autosomal recessive heterogeneous urea
cycle disorder, which leads to the accumulation of argininosuccinic acid in the blood and urine. We aimed to
perform genetic test to the patient and help clinician to diagnose precisely.
Case presentation: In this study, we use next generation sequencing (NGS) and exon trapping to analysis the
family members. We identified compound heterozygous mutations of the argininosuccinate lyase (ASL) gene in a
Chinese Han ASAuria patient. The c.434A>G (p.(D145G)) mutation in exon 5 was shown by exon trapping to select
for the formation of an alternative transcript deleted for exon 5. The c.1366C>T (p.(R456W)) mutation had been
previously reported in an Italian patient.
Conclusions: This is the first report of a missense mutation driving alternative splicing which results in the loss of
exon 5 in ASAuria. This study also demonstrates the value of NGS in the identification of mutations and molecular
diagnosis for ASAuria families.
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Background
Argininosuccinic aciduria (ASAuria; OMIM 207900) is
an inborn error of metabolism affecting the urea cycle. It
is caused by mutations in the argininosuccinate lyase
(ASL) gene, the protein product of which cleaves argini-
nosuccinate to fumarate and arginine. The prevalence of
ASAuria is 1 in 70,000 live births making it the second
most common urea cycle disorder [1].
Urea cycle disorders result from defects in the metab-
olism of waste nitrogenous compounds derived from the
breakdown of proteins and other nitrogen-containing
molecules. Patients accumulate the nitrogen in the form
of ammonia in plasma, which is a highly toxic substance
that is not excreted. Six genetic forms have been identi-
fied, arising from inherited deficiencies of catalytic en-
zymes (CPS1, OTC, ASS1, ASL, ARG1) and a cofactor-
producing enzyme (NAGS). With the single exception of
OTC which is X-linked, all show autosomal recessive in-
heritance [2].
The clinical presentation of patients with ASAuria is
variable. Generally, the disease has two forms, a severe
neonatal form and a milder late onset form [3]. The se-
vere neonatal form is characterized by hyperammonemia
within the first few days of life with poor feeding, vomit-
ing, lethargy, and seizures, with subsequent progression
to coma. The late onset form manifests late in infancy or
in childhood; it presents with mental retardation, vomit-
ing, failure to thrive and behavioral problems [4].
The clinical diagnosis is confirmed by measuring am-
monia and argininosuccinate levels in plasma [5]. The
human ASL gene spans approximately 17 kb (RefSeq
NG_009288.1) and comprises 16 exons (RefSeq
NM_001024943.1 coding region starts at exon 1), lo-
cated on chromosome 7cen-q11.2 [6]. Previous studies
have reported alternatively spliced transcripts of ASL in
all investigated cells and tissues, mainly involving dele-
tions of exon 2 and 7 [7–9].
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A customized capture array (NimbleGen, Roche, USA)
was designed to capture genes including the six recog-
nized urea cycle disorder genes plus SLC25A13 and
SLC25A15, encoding citrin and mitochondrial ornithine
transporter, respectively, both of which play important
roles in the urea cycle. Until now, there are 39 unique
DNA variants reported by LOVD (http://chromium.-
lovd.nl/LOVD2/home.php?select_db=ASL) and the
number of reported mutations is still quite small. Our
study aimed to identify causative mutations by NGS on
a Chinese pedigree with ASAuria and to analyze the
underlying molecular defects.
Case presentation
The patient (2.1), a Chinese Han boy, was brought to
the Shenzhen Maternal and Child Healthcare Hospital at
6 days of age with jaundice, poor feeding, vomiting but
without crying. At 7 days of age, he was admitted to the
hospital with presumed neonatal sepsis, neonatal con-
junctivitis and neonatal jaundice. He was lethargic with
poor responses and had ocular hyperemia with purulent
secretions from eyes. The patient was kept NPO for sev-
eral hours. Intravenous dextrose containing solution was
given and he was treated with antibiotics for presumed
sepsis. After one day at the hospital, his condition be-
came worse with hypotonia and coma. Biochemical ana-
lysis revealed hyperammonemia (456 μmol/L, normal
range 18–72 μmol/L) in the serum, which persisted on
the following days (568 μmol/L). Tandem Mass Spec-
trometry revealed the serum amino acids levels : citrul-
line 127.2 μmol/L (4–24 μmol/L), phenylalanine
23.1 μmol/L (25–120 μmol/L), tyrosine 13.99 μmol/L
(25–150 μmol/L), valine 68.6 μmol/L (80–250 μmol/L),
He was treated with amikacin and arginine to reduce the
level of serum ammonia, after 3 days, the serum ammo-
nia decreased to 51 μmol/L, on the ninth day after ad-
mission to the hospital, the level of serum ammonia was
21 μmol/L and he was sent out of the hospital.
After leaving the hospital, he was followed regularly
and treated with low-protein diet, oral arginine tablets,
sodium benzoate. His daily protein intake was restricted
to ≤1.5 g/Kg per day and serum ammonia was main-
tained at ≤80 μmol/L. At 4 years of age, the patient pre-
sented acceptable physical development, but his
language and motor development slightly behind his
peers’ children. He had a six year old sister who pre-
sented a normal condition. The pedigree is shown in
Fig. 1.
Following informed consent, the patient, his parents
and older sister’s peripheral blood (3 ml) were collected
and anticoagulated with EDTA. Total DNA was ex-
tracted using the QIAamp DNA extraction kit (Qiagen,
Hilden, Germany), according to the manufacturer’s
protocol.
DNA samples were sequenced using Microarray-based
NGS. We designed a custom array from Roche Nimble-
Gen (Madison, USA) to capture exons (including the
10 bp flanking either side of each) of genes including 8
genes associated with urea cycle disorders. Genomic
DNA was fragmented into fragments ranging from 200–
300 bp using an ultrasonoscope (Covaris S2, Massachu-
setts, USA). Primers and adapters were then ligated to
the purified DNA fragments to construct the library.
The library was amplified by PCR and hybridized to the
capture array. Samples were sequenced on Illumina
HiSeq2500 Analyzers (Illumina, San Diego, USA) for
90 cycles to generate 90 bp paired-end reads. Image ana-
lysis and base calling were performed using the Illumina
Pipeline [10].
Exon 5 and exon 16 of the ASL gene were amplified




AAAGCCCAGCAACGAGG), 0.25 mM dNTPs and 1U
Taq polymerase in 1 × buffer with annealing
temperature at 64 and 67° separately. PCR products
were purified using the QIA PCR purification kit
(Qiagen, Crawley, UK).
Fig. 1 ASL genotypes, determined by NGS using a urea cycle
disorders chip, are indicated. Pedigree showing autosomal recessive
inheritance of argininosuccinic aciduria. Solid symbol, affected; open
symbol, unaffected; arrow, proband (P)
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To study the function of the c.434A>G (p.(D145G))
mutation in exon 5, we performed exon trapping
studies in vitro [11]. We amplified a genomic frag-
ments containing exon 5, intron 5 and exon 6 with
primers F-CCGTGTTGTCCCAACCTTGA and R-
GGGCTGTGCTAGAGGGGA from the patient and
from a normal individual, respectively. The product
fragments were cloned into the pSPL3exon trapping
vector(Invitrogen, Carlsbad, CA). Wild type (WT) and
mutant plasmids were then transfected into the COS7
cell line using Lipofectamine2000 (Invitrogen, Carls-
bad, CA) respectively. After culture for 48 hours, total
RNA was extracted using Trizol (TaKaRa, Dalian,
China). 5 μg RNA was reverse transcribed to cDNA in a
total volume of 20 μl with superscript II RNAse H-reverse
transcriptase and oligo-dT priming (TaKaRa, Dalian,
China). The cDNA was amplified using vector pri-
mersSD6(TCTGAGTCACCTGGACAACC) and SA2
(ATCTCAGTGGTATTTGTGAGC), PCR products were
separated on a 2 % TBE agarose gel. After purification,
amplification products were characterized by direct
sequencing.
NGS identified ten variants in total, located in four dif-
ferent urea cycle related genes in the patient (Additional
file 1: Table S1). These included compound heterozygous
mutations in ASL, of which one was a mutation:
c.434A>G (p.(D145G)) located in exon 5; the other
c.1366C>T mutation in exon 16 had been reported pre-
viously [4]. The patient’s father and sister were heterozy-
gous for c.434A>G and his mother was heterozygous for
c.1366C>T. We validated the results of the NGS by dir-
ect sequencing (Fig. 2a-b).
We performed an in vitro exon trapping assay to
analyze the effects of c.434A>G upon splicing of the tran-
script. The gel electrophoresis of the cDNA products is
shown in Fig. 3a. Lane2 contains cDNA products trapped
from the c.434A>G mutant construct, showing a single
band of ~350 bp (ASL-M). Lane 3 contains cDNA prod-
ucts trapped from the wild type control construct, show-
ing two bands of ASL-C1 (~450 bp) and ASL-C2
(~350 bp). Direct sequencing showed that the sequence of
ASL-M was exactly the same as ASL-C2, with alternative
splicing resulting in the deletion of exon 5 (Fig. 3b). The
sequence of ASL-C1 was identical to the reference se-
quence, with no alternative splicing (Fig. 3c). We drew a
schematic diagram to describe the mutation c.434A>G led
to the skipping of exon 5 (Fig. 3d). Functional analysis of
this mutation demonstrates that the substitution of nu-
cleotide (c.434A>G) leads to the complete loss of exon 5.
Discussion
In this study, we identified compound heterozygous mu-
tations in ASL using NGS, confirming the clinical diag-
nosis of ASAuria. We developed an in vitro exon
trapping assay which demonstrated that the mutation
c.434A>G completely abolished normal splicing of exon
5. At the beginning, We have amplified the cDNA
reverse-transcripted from the patient’s mutant mRNA,
however because of high numbers of ASL transcripts (10
transcripts), which makes RT-PCR is not suitable for
analyzing alternative splicing of the transcript. Further-
more, the quantity of RNA is hard to extract enough
from patient. While additional factors could poten-
tially influence the splicing pattern in vivo, the re-
stricted availability of patient samples makes the exon
trapping assay a useful tool for mutation assessment.
Also, there is some other physiological skipping of
various ASL exons than 2 and 7 detected by Linne-
bank and colleagues (2000).
Fig. 2 Direct sequencing of ASL (NCBI Reference Sequence: NM_001024943.1) in the patient 2.1 (other family members’ data not shown). a The
heterozygous mutation c.434A>G (p.(D145G)) in exon 5 (arrow). b The heterozygous mutation c.1366C>T (p.(R456W)) in exon 16 (arrow)
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A previous report described the other mutation,
c.1366C>T (p.(R456W)), which involves a conserved ar-
ginine in the terminal alpha helix of the protein. Substi-
tution with tryptophan is predicted to cause a
displacement and to shift the position of glutamine454
[4]. Our data suggest that compound heterozygosity for
these two mutations is unlikely to result in translation of
fully functional ASL protein.
The molecular diagnosis of the urea cycle disorders is
an important area for development. Although determin-
ation of ASL activity in cultured fibroblasts or erythro-
cytes is a reliable method to confirm the diagnosis, it
requires the availability of patient samples and is a com-
plex method only available in a few laboratories world-
wide. However, molecular analysis is more feasible and
potentially efficient. Therefore, we recommend NGS
technologies to diagnosis ASAuria and other urea cycle
disorders.
Overall, this is the first report of a pathogenic mis-
sense mutation causing alternative splicing which results
the loss of exon 5 in ASAuria. It helps us understand
the molecular mechanism of ASL. This study also dem-
onstrates the value of NGS in the identification of muta-
tions and molecular diagnosis in these families.
Conclusions
In conclusion, we identified compound heterozygous
mutations in ASL using NGS, confirming the clinical
diagnosis of ASAuria. The c.434A>G (p.(D145G)) muta-
tion in exon 5 was shown by exon trapping to select for
the formation of an alternative transcript deleted for
exon 5. This is the first report of a missense mutation
driving alternative splicing which results in the loss of
exon 5 in ASAuria.
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Fig. 3 Functional analysis of the mutation c.434A>G in ASL and its effect on mRNA splicing. a cDNA gel electrophoresis: 1, DNA molecular
weight marker (100–1000 bp); 2, c.434A>G mutated cDNA; 3, wild type cDNA; 4, pSPL3 plasmid control. b Sequence of the mutated cDNA
amplification product ASL-M and wild type cDNA amplification product ASL-C2, both showing exon 5 deletion. The red box represents exon 6.
c Sequence of wild type cDNA amplification product ASL-C1 showing the reference sequence. The dark blue box represents exon 5, red box
represents exon 6. d Scheme for the effects of the mutation c.434A>G. ASL-M is exactly the same as ASL-C2 with splicing out of exon 5. The
sequence of ASL-C1 identical to the reference sequence, without alternative splicing
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